Safety issues with glucagon-like peptide-1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): Data from randomized controlled trials.
about
Glucagon-like peptide-1 receptor agonists and atrial fibrillation: a systematic review and meta-analysis of randomised controlled trials.Incretin-based therapies and risk of pancreatic cancer in patients with type 2 diabetes: A meta-analysis of randomized controlled trials.Pharmacological management of type 2 diabetes: what's new in 2017?Incretin-Based Therapies: Revisiting Their Mode of Action.Targeting postprandial glycaemia in children with diabetes: Opportunities and challenges.Can we exonerate GLP-1 receptor agonists from blame for adverse pancreatic events?
P2860
Safety issues with glucagon-like peptide-1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): Data from randomized controlled trials.
description
2017 nî lūn-bûn
@nan
2017 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2017 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
name
Safety issues with glucagon-li ...... randomized controlled trials.
@ast
Safety issues with glucagon-li ...... randomized controlled trials.
@en
type
label
Safety issues with glucagon-li ...... randomized controlled trials.
@ast
Safety issues with glucagon-li ...... randomized controlled trials.
@en
prefLabel
Safety issues with glucagon-li ...... randomized controlled trials.
@ast
Safety issues with glucagon-li ...... randomized controlled trials.
@en
P2093
P2860
P356
P1476
Safety issues with glucagon-li ...... m randomized controlled trials
@en
P2093
Alessia Scatena
Barbara Cresci
Besmir Nreu
Edoardo Mannucci
Giorgio Sesti
P2860
P304
P356
10.1111/DOM.12926
P577
2017-06-20T00:00:00Z